Biotech
Third Harmonic Bio
Third Harmonic Bio raises $200M Series C at $750M valuation
$200M
Total Raised
Series C
Latest Round
2019
Founded
100+
Employees
325 Vassar Street, Cambridge, MA 02139
1 min read
Quick Facts
Valuation
$750M
Latest Round Size
$200M
Latest Round Date
November 2024
Third Harmonic Bio: Series C Funding Round
Third Harmonic Bio has successfully raised $200M in Series C funding, reaching a valuation of $750M.
Company Overview
Dicerna-based RNAi therapeutics
Funding Details
The Series C round was led by ARCH Venture Partners, with participation from Polaris Partners, RA Capital Management, GV.
Company Information
- Headquarters: 325 Vassar Street, Cambridge, MA 02139
- Founded: 2019
- Employees: 100+
- Category: Biotech
Investment
Third Harmonic Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series C
- Polaris Partners: Verified investor in Series C
- RA Capital Management: Verified investor in Series C
- GV: Verified investor in Series C
Key Investors
ARCH Venture Partners
Lead Investor
Verified investor in Series C
Polaris Partners
Investor
Verified investor in Series C
RA Capital Management
Investor
Verified investor in Series C
GV
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M